Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation

Cancer Letters

Volumn 109, Issue 1-2, 1996, Pages 203-209

  Hu, Yan Ping ^a   Chapey, Christiane ^a   Robert, Jacques ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

Azidopine binding; Doxorubicin intracellular accumulation; MDR

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; AZIDOPINE; CYCLOSPORIN A; DOXORUBICIN; GLYCOPROTEIN P; NICARDIPINE; NIFEDIPINE; QUINIDINE; QUININE; VALSPODAR; VERAPAMIL;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG ACCUMULATION; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

EID: 0030568089     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(96)04454-0     Document Type: Article

References (28)

1. [1] Akiyama, S.I., Cornwell, M.M., Kuwano, K., Pastan, I. and Gottesman, M.M. (1988) Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog, Mol. Pharmacol., 33, 144-147.
2. [2] Basu, A. (1993) The potential of protein kinase-C as a target for anticancer treatment, Pharmacol. Ther., 59, 257-280.
3. [3] Beck, W.T. and Qian, X.D. (1992) Photoaffinity substrates for P-glycoprotein, Biochem. Pharmacol., 43, 89-93.
4. [4] Beck, W.T., Danks, M.K., Wolverton, J.S., Chen, M., Granzen, B., Kim, R. and Suttle, D.P. (1994) Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase-II, Adv. Pharmacol., 229B, 145-167.
5. [5] Bennis, S., Ichas, F. and Robert, J. (1995) Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemic cell line, Int. J. Cancer, 62, 283-290.
6. [6] Bruggemann, E.P., Germann, U.A., Gottesman, M.M. and Pastan, I. (1989) Two different regions of P-glycoprotein are photoaffinity labeled by azidopine. J. Biol. Chem., 264, 15483-15488.
7. [7] Bruggemann, E.P., Currier, S.J., Gottesman, M.M. and Pastan, I. (1992) Characterization of the azidopine and vinblastine binding site of P-glycoprotein, J. Biol. Chem., 267, 21020-21026.
8. [8] Endicott, LA. and Ling, V. (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance, Annu. Rev. Biochem., 58, 137-171.
9. [9] Ford, J.M. and Hait, W.N. (1990) Pharmacology of drugs that alter multidrug resistance in cancer, Pharmacol. Rev., 42, 155-199.
10. [10] Foxwell, B.M.J., Mackie, A., Ling, V. and Ryffel, B. (1989) Identification of the multidrug resistance-related P-glycoprotein as a cyclosporin-binding protein, Mol. Pharmacol., 36, 543-546.
11. [11] Georges, E., Sharom, F.J. and Ling, V. (1990) Multidrug resistance and chemosensitization: therapeutic implications for cancer chemotherapy, Adv. Pharmacol., 21, 185-220.
12. [12] Gottesman, M.M. and Pastan, I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu. Rev. Biochem., 62, 385-427.
13. [13] Greenberger, L.M. (1993) Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domain-6 and domain-12, J. Biol. Chem., 268, 11417-11425.
14. [14] Herzog, C.E., Tsokos, M., Bates, S.E. and Fojo, A.T. (1993) Increased MDR1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists, J. Biol. Chem., 268, 2946-2952.
15. [15] Hu, Y.P. and Robert, J. (1995) Azelastine and flazelastine as reversing agents of multidrug zesistance: pharmacological and molecular studies, Biochem. Pharmacol., 50, 167-175.
16. [16] Huet, S., Schott, B. and Robert, J. (1992) P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines, Br. J. Cancer, 65, 538-544.
17. [17] Kajiji, S., Talbot, F., Grizzuti, K., Van Dyke-Phillips, V., Agresti, M., Safa, A.R. and Gros, P. (1993) Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain-11 as a putative drug binding site, Biochemistry, 32, 4185-4194.
18. 939/341, Biochemistry, 33, 5041-5048.
19. [19] Keizer, H.G., Schuurhuis, G.J., Broxterman, H.J., Lankelma, J., Schoonen, G.E.J., van Rijn, J., Pinedo, H.M. and Joenje, H. (1989) Correlation of multidrug resistance with decreased drug accumulation, altered cellular distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells, Cancer Res., 49, 2988-2993.
20. [20] Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of head of bacteriophage T4, Nature, 227, 680-685.
21. [21] Muller, C., Bailly, J.D., Goubin, F., Laredo, J., Jaffrézou, J.P., Bordier, C. and Laurent, G. (1994) Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines, Int. J, Cancer, 56, 749-754.
22. [22] Nielsen, D. and Skovsgaard, T. (1992) P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines, Biochim. Biophys. Acta, 1139, 169-183.
23. [23] Safa, A.R. (1992) Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells, Cancer Invest., 10, 295-305.
24. [24] Schott, B., Bennis, S., Pourquier, P., Ries, C., Londos-Gagliardi, D. and Robert, J. (1993) Differential overexpression of mdr1 genes in multidrug-resistant rat glioblastoma cell lines selected with doxorubicin or vincristine, Int. J. Cancer, 55, 115-121.
25. [25] Shen, D.W., Cardarelli, C., Hwang, J., Cornwell, M., Richert, N., Ishii, S., Pastan, I. and Gottesman, M. (1986) Multiple drug-resistant KB carcinoma cells independently selected for high level resistance to colchicine, adriamycin or vinblastine show changes in expression of specific proteins, J. Biol. Chem., 261, 7762-7770.
26. [26] Tamai, I. and Safa, A.R. (1990) Competitive interaction of cyclosporins with the vinca alkaloid-binding site of P-glycoprotein in multidrug resistant cells, J. Biol. Chem., 265, 16509-16513.
27. [27] Zhang, X., Collins, K.I. and Greenberger, L.M. (1995) Functional evidence that transmembrane 12 and the loop between transmembrane 11 and 12 form part of the drug-binding domain in P-glycoprotein encoded by MDR1, J. Biol. Chem., 270, 5441-5448.
28. [28] Zijlstra, J.G., De Vries, E.G.E. and Mulder, N.H. (1987) Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line, Cancer Res., 47, 1780-1784.